Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | THPO | P40225 | 1/20 | 0.52 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.39 |
| ▸ | TYMS | P04818 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | FDPS | P14324 | 7/20 | 0.32 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26042675 | 0.93 | GABBR2 (0.50) | GABBR2CYP1A2TSHRTHPOGABBR1 | |
| SCHEMBL25670650 | 0.87 | GABBR2 (0.46) | GABBR2CYP1A2TSHRTHPOGABBR1 | |
| SCHEMBL6678291 | 0.82 | TYMS (0.55) | LMNABLMGRM4TYMS | |
| SCHEMBL11287065 | 0.78 | GABBR2 (0.68) | GABBR2CYP1A2TSHRTHPOGABBR1 | |
| SCHEMBL11347827 | 0.78 | GABBR2 (0.68) | GABBR2CYP1A2TSHRTHPOGABBR1 | |
| SCHEMBL10385227 | 0.76 | FDPS (0.59) | GABBR2CYP1A2TSHRTHPOGABBR1 | |
| SCHEMBL11319722 | 0.75 | GABBR2 (0.65) | GABBR2CYP1A2TSHRTHPOGABBR1 | |
| SCHEMBL603589 | 0.75 | GABBR2 (0.65) | GABBR2CYP1A2TSHRTHPOGABBR1 | |
| SCHEMBL9713364 | 0.75 | TYMS (0.52) | LMNABLMGRM4TYMS | |
| SCHEMBL3822930 | 0.75 | GABBR2 (0.41) | GABBR2TSHRGABBR1GRM4FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807641-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | UNIV ROCKEFELLER (US) | 2023-08-31 | — | — | US | disclosed |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11807641-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | GABBR2 4050/4885CYP1A2 4271/4885TSHR 3550/4885 |
| US-20230272010-A1 | ANTIBACTERIAL SYNTHETIC-BIOINFORMATIC NATURAL PRODUCTS AND USES THEREOF | LSS, NRDC, SPOUT1 | GABBR2 3366/4885CYP1A2 3192/4885TSHR 4663/4885 |
| US-11661418-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | GABBR2 4050/4885CYP1A2 4271/4885TSHR 3550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.